..., estimated at 20.1 per 100,000 live births in 2019. That number is doubled for non-Hispanic Black women. “Approximately two-thirds of the 700 pregnancy-related deaths are considered preventable,” the statement reads. It’s time to take a closer look. Thrombosis and hemorrhage during pregnancy and postpartum...)

...? Microangiopathic Emergencies (Saturday, 4:00 p.m. – 5:15 p.m., Convention Center, Room 29). Ever needed help with HELLP? Jennifer Jury McIntosh, DO, will discuss this diagnosis (i.e., hemolysis, elevated liver enzymes, and low platelets) and other microangiopathies that present in the context of pregnancy...)

... in the literature. However, pregnancy is an oft unrecognized, though serious risk factor for sickling associated with SCD and is associated with high morbidity and mortality. Pregnant women with SCD are known to experience numerous obstetric complications, but their risk of death and other complications increases...)

... in live birth rate with enoxaparin use in women without thrombophilia in a prior double-blind randomized trial. Similarly, the ALIFE2 study, led by Dr. Saskia Middeldorp, investigated the role of LMWH in prevention of pregnancy loss, specifically in women who inherited thrombophilia and confirmed a lack...)

... on the genetic diversity of the Rh blood group system as the cause of incompatibilities during pregnancy and following blood transfusion.” Her work to change the way hematologists are able to genotype blood group antigens has been particularly important for patients in need of long-term transfusion support who...)

... on the genetic diversity of the Rh blood group system as the cause of incompatibilities during pregnancy and following blood transfusion.” Her work to change the way hematologists are able to genotype blood group antigens has been particularly important for patients in need of long-term transfusion support who...)

... models for pediatric thrombosis in the session Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism (Monday, 2:45 p.m., Convention Center, Room 33). Dr. Jaffray will present the abstract “ Multicenter Study...)

... the development of less toxic iron chelators, exploration of iron-restrictive therapies for hemoglobinopathies and polycythemia vera, and understanding the mechanisms and impact of iron deficiency in pregnancy and postnatal development, infection, and chronic disease processes, including heart failure and chronic...)

... only the beginning, as reduction of thrombotic risk, safety in pregnancy and normalization of overall survival emerged as meaningful outcomes of treatment. Treatments targeting C5 (eculizumab, ravulizumab), C3 (pegcetacoplan), C5a (avacopan) and C1a (sutimlimab) are now approved, with pegcetacoplan...)

...-replete variety show (but with a lot more, well, science ). Emerging themes include maternal health with Special-Interest Sessions addressing hematology and pregnancy, as well as obstetric management and complications associated with specific hematologic conditions such as sickle cell disease...)

... iron pathobiology in pregnancy, infectious disease, inflammatory disorders such as chronic kidney disease, and iron overload disorders such as hereditary hemochromatosis and hemoglobinopathies.” Looking at the field today, Dr. Nemeth underscored numerous breakthroughs shaping our current...)

... and Bone Marrow Failure Hematology and Aging Hematology and Pregnancy Interplay Between Coagulation and Malignancy Myeloid Development Streamlining Hematology Clinical Trials Translational Molecular Diagnostics Tumor Immune Interactions in Lymphoid Malignancies   5. See What the 2021...)